Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids

• Príomhchruthaitheoirí: Mohamed Elbadawy (Údar), Kiwamu Tanabe (Údar), Haru Yamamoto (Údar), Yusuke Ishihara (Údar), Maria Mochizuki (Údar), Amira Abugomaa (Údar), Hideyuki Yamawaki (Údar), Masahiro Kaneda (Údar), Tatsuya Usui (Údar), Kazuaki Sasaki (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Non-alcoholic steatohepatitis (NASH) is known to progress to cirrhosis and hepatocellular carcinoma in some patients. Although NASH is associated with abnormal mitochondrial function related to lipid metabolism, mechanisms for the development and effective treatments are still unclear. Therefore, ne...